Analysts Offer Insights on Healthcare Companies: Stryker (NYSE: SYK), Dicerna Pharma (NASDAQ: DRNA) and Roche Holding AG (Other OTC: RHHVF)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Stryker (SYKResearch Report), Dicerna Pharma (DRNAResearch Report) and Roche Holding AG (RHHVFResearch Report) with bullish sentiments.

Stryker (SYK)

In a report released today, Pito Chickering from Deutsche Bank maintained a Buy rating on Stryker, with a price target of $285.00. The company’s shares closed last Thursday at $258.16, close to its 52-week high of $268.04.

According to TipRanks.com, Chickering is a 4-star analyst with an average return of 15.4% and a 66.0% success rate. Chickering covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Zimmer Biomet Holdings, and Baxter International.

Stryker has an analyst consensus of Moderate Buy, with a price target consensus of $279.85, which is an 8.1% upside from current levels. In a report issued on July 20, BTIG also maintained a Buy rating on the stock with a $282.00 price target.

See today’s analyst top recommended stocks >>

Dicerna Pharma (DRNA)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Dicerna Pharma today and set a price target of $42.00. The company’s shares closed last Thursday at $38.40, close to its 52-week high of $40.14.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 16.1% and a 38.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.

Dicerna Pharma has an analyst consensus of Strong Buy, with a price target consensus of $40.80, representing a 6.0% upside. In a report issued on July 14, RBC Capital also maintained a Buy rating on the stock with a $35.00 price target.

Roche Holding AG (RHHVF)

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Roche Holding AG on July 20 and set a price target of CHF425.00. The company’s shares closed last Wednesday at $386.50, close to its 52-week high of $390.01.

According to TipRanks.com, Papadakis is a 2-star analyst with an average return of 1.1% and a 53.8% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Roche Holding, Grifols SA, and Sanofi.

Currently, the analyst consensus on Roche Holding AG is a Moderate Buy with an average price target of $405.31, implying a 5.0% upside from current levels. In a report released yesterday, Cowen & Co. also initiated coverage with a Buy rating on the stock with a CHF369.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.